Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients.
COVID-19
SARS-CoV-2
acute respiratory distress syndrome
liver chemistries
liver injury
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
01
04
2022
received:
17
12
2021
accepted:
10
04
2022
pubmed:
13
4
2022
medline:
11
6
2022
entrez:
12
4
2022
Statut:
ppublish
Résumé
The coronavirus disease of 2019 (COVID-19) causes considerable mortality worldwide. We aimed to investigate the frequency and predictive role of abnormal liver chemistries in different age groups. Patients with positive severe acute respiratory distress syndrome-coronavirus-2 (SARS-CoV-2) polymerase chain reaction (PCR) test between 03/2020-07/2021 at the Vienna General Hospital were included. Patients were stratified for age: 18-39 vs. 40-69 vs. ≥70 years (y). Aspartate aminotransferase (AST), alanine-aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) and total bilirubin (BIL) were recorded. 900 patients (18-39 years: 32.2%, 40-69 years: 39.7%, ≥70 years: 28.1%) were included. Number of comorbidities, median D-dimer and C-reactive protein increased with age. During COVID-19, AST/ALT and ALP/GGT levels significantly increased. Elevated hepatocellular transaminases (AST/ALT) and cholestasis parameters (ALP/GGT/BIL) were observed in 40.3% (n = 262/650) and 45.0% (n = 287/638) of patients respectively. Liver-related mortality was highest among patients with pre-existing decompensated liver disease (28.6%, p < .001). 1.7% of patients without pre-existing liver disease died of liver-related causes, that is consequences of hepatic dysfunction or acute liver failure. Importantly, COVID-19-associated liver injury (16.0%, p < .001), abnormal liver chemistries and liver-related mortality (6.5%, p < .001) were most frequent among 40-69 years old patients. Elevated AST and BIL after the first positive SARS-CoV-2 PCR independently predicted mortality in the overall cohort and in 40-69 years old patients. Almost half of the COVID-19 patients exhibit abnormal hepatocellular and cholestasis-related liver chemistries with 40-69 years old patients being at particularly high risk for COVID-19-related liver injury and liver-related mortality. Elevated AST and BIL after SARS-CoV-2 infection are independent predictors of mortality, especially in patients aged 40-69 years.
Sections du résumé
BACKGROUND AND AIMS
The coronavirus disease of 2019 (COVID-19) causes considerable mortality worldwide. We aimed to investigate the frequency and predictive role of abnormal liver chemistries in different age groups.
METHODS
Patients with positive severe acute respiratory distress syndrome-coronavirus-2 (SARS-CoV-2) polymerase chain reaction (PCR) test between 03/2020-07/2021 at the Vienna General Hospital were included. Patients were stratified for age: 18-39 vs. 40-69 vs. ≥70 years (y). Aspartate aminotransferase (AST), alanine-aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) and total bilirubin (BIL) were recorded.
RESULTS
900 patients (18-39 years: 32.2%, 40-69 years: 39.7%, ≥70 years: 28.1%) were included. Number of comorbidities, median D-dimer and C-reactive protein increased with age. During COVID-19, AST/ALT and ALP/GGT levels significantly increased. Elevated hepatocellular transaminases (AST/ALT) and cholestasis parameters (ALP/GGT/BIL) were observed in 40.3% (n = 262/650) and 45.0% (n = 287/638) of patients respectively. Liver-related mortality was highest among patients with pre-existing decompensated liver disease (28.6%, p < .001). 1.7% of patients without pre-existing liver disease died of liver-related causes, that is consequences of hepatic dysfunction or acute liver failure. Importantly, COVID-19-associated liver injury (16.0%, p < .001), abnormal liver chemistries and liver-related mortality (6.5%, p < .001) were most frequent among 40-69 years old patients. Elevated AST and BIL after the first positive SARS-CoV-2 PCR independently predicted mortality in the overall cohort and in 40-69 years old patients.
CONCLUSIONS
Almost half of the COVID-19 patients exhibit abnormal hepatocellular and cholestasis-related liver chemistries with 40-69 years old patients being at particularly high risk for COVID-19-related liver injury and liver-related mortality. Elevated AST and BIL after SARS-CoV-2 infection are independent predictors of mortality, especially in patients aged 40-69 years.
Identifiants
pubmed: 35412018
doi: 10.1111/liv.15274
pmc: PMC9115240
doi:
Substances chimiques
gamma-Glutamyltransferase
EC 2.3.2.2
Aspartate Aminotransferases
EC 2.6.1.1
Alanine Transaminase
EC 2.6.1.2
Alkaline Phosphatase
EC 3.1.3.1
Bilirubin
RFM9X3LJ49
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1297-1307Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
J Hepatol. 2020 Oct;73(4):807-816
pubmed: 32437830
Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):309-311
pubmed: 32558697
Hepatology. 2020 Aug;72(2):389-398
pubmed: 32359177
Liver Int. 2021 Jan;41(1):20-32
pubmed: 33190346
Am J Gastroenterol. 2017 Jan;112(1):18-35
pubmed: 27995906
J Hepatol. 2020 Sep;73(3):566-574
pubmed: 32298767
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346
pubmed: 32214079
FEBS J. 2020 Sep;287(17):3633-3650
pubmed: 32446285
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Transplant Proc. 2021 May;53(4):1132-1137
pubmed: 33846012
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Allergy. 2020 Jul;75(7):1742-1752
pubmed: 32239761
JAMA Netw Open. 2020 Jun 1;3(6):e2011335
pubmed: 32525549
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
J Hepatol. 2021 Mar;74(3):567-577
pubmed: 33035628
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Liver Int. 2020 May;40(5):998-1004
pubmed: 32170806
J Hepatol. 2020 Nov;73(5):1231-1240
pubmed: 32553666
J Hepatol. 2021 Sep;75(3):742-744
pubmed: 34090927
Gut. 2021 Apr;70(4):807-809
pubmed: 32669289
BMJ Case Rep. 2020 Nov 9;13(11):
pubmed: 33168538
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Hepatology. 2020 Nov;72(5):1864-1872
pubmed: 32702162
Allergy. 2021 Feb;76(2):428-455
pubmed: 33185910
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Am J Gastroenterol. 2021 May 1;116(5):1077-1082
pubmed: 33464757
Hepatol Int. 2020 Sep;14(5):690-700
pubmed: 32623632
J Hepatol. 2021 Sep;75(3):739-740
pubmed: 33753154
Aliment Pharmacol Ther. 2020 Aug;52(4):584-599
pubmed: 32638436
Liver Int. 2022 Jun;42(6):1297-1307
pubmed: 35412018
Clin Infect Dis. 2021 Dec 6;73(11):e4208-e4213
pubmed: 32173725
J Pers Med. 2021 Dec 01;11(12):
pubmed: 34945736
Aliment Pharmacol Ther. 2020 Jul;52(2):267-275
pubmed: 32402090
BMJ. 2020 May 22;369:m1985
pubmed: 32444460